Hemophilia Gene Therapies Should Have REMS For Approval, National Hemophilia Foundation Says

Agency should require physician training, facility certification, and patient registry as a condition for approving BioMarin's and CSL Behring’s investigational gene therapies, the advocacy group says. It calls for treatment to be limited to the population studied with no-off label use.